25 XP   0   0   10

Enveric Biosciences Inc
Buy, Hold or Sell?

Let's analyse Enveric together

PenkeI guess you are interested in Enveric Biosciences Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Enveric Biosciences Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Enveric Biosciences Inc

I send you an email if I find something interesting about Enveric Biosciences Inc.

Quick analysis of Enveric (30 sec.)










What can you expect buying and holding a share of Enveric? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
10.3%

What is your share worth?

Current worth
$0.52
Expected worth in 1 year
$-1.10
How sure are you?
51.3%

+ What do you gain per year?

Total Gains per Share
$-1.62
Return On Investment
-179.5%

For what price can you sell your share?

Current Price per Share
$0.90
Expected price per share
$0.649 - $1.19
How sure are you?
50%

1. Valuation of Enveric (5 min.)




Live pricePrice per Share (EOD)

$0.90

Intrinsic Value Per Share

$-24.91 - $-12.99

Total Value Per Share

$-24.39 - $-12.48

2. Growth of Enveric (5 min.)




Is Enveric growing?

Current yearPrevious yearGrowGrow %
How rich?$3.7m$21.5m-$15.9m-283.2%

How much money is Enveric making?

Current yearPrevious yearGrowGrow %
Making money-$4.3m-$4.6m$314.1k7.3%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Enveric (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#776 / 1010

Most Revenue
#952 / 1010

Most Profit
#403 / 1010

Most Efficient
#410 / 1010

What can you expect buying and holding a share of Enveric? (5 min.)

Welcome investor! Enveric's management wants to use your money to grow the business. In return you get a share of Enveric.

What can you expect buying and holding a share of Enveric?

First you should know what it really means to hold a share of Enveric. And how you can make/lose money.

Speculation

The Price per Share of Enveric is $0.9. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Enveric.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Enveric, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.52. Based on the TTM, the Book Value Change Per Share is $-0.40 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.23 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Enveric.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.47-52.3%-0.65-72.6%-0.56-62.5%-0.64-71.0%-0.44-49.0%
Usd Book Value Change Per Share0.1820.4%-0.40-44.9%-0.23-25.7%-0.05-5.3%0.011.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%6,741.29749,032.7%3,464.42384,935.5%
Usd Total Gains Per Share0.1820.4%-0.40-44.9%-0.23-25.7%6,741.25749,027.4%3,464.43384,937.0%
Usd Price Per Share1.30-2.18-1.71-1.76-2.40-
Price to Earnings Ratio-0.69--0.92--0.95--1.52--56.89-
Price-to-Total Gains Ratio7.09--1.68-7.30-2.86--196.24-
Price to Book Ratio2.51-3.94-0.61-2.16-33.14-
Price-to-Total Gains Ratio7.09--1.68-7.30-2.86--196.24-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.9
Number of shares1111
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.006,741.29
Usd Book Value Change Per Share-0.40-0.05
Usd Total Gains Per Share-0.406,741.25
Gains per Quarter (1111 shares)-448.697,489,524.67
Gains per Year (1111 shares)-1,794.7529,958,098.70
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1795-180529958311-21329958089
20-3589-360059916623-42659916188
30-5384-539589874934-63889874287
40-7179-7190119833246-851119832386
50-8974-8985149791557-1064149790485
60-10768-10780179749869-1277179748584
70-12563-12575209708180-1490209706683
80-14358-14370239666492-1702239664782
90-16153-16165269624803-1915269622881
100-17947-17960299583115-2128299580980

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%3.036.00.07.7%19.089.00.017.6%
Book Value Change Per Share1.03.00.025.0%6.06.00.050.0%10.010.00.050.0%18.020.01.046.2%40.065.03.037.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%2.00.018.010.0%4.00.035.010.3%4.00.0104.03.7%
Total Gains per Share1.03.00.025.0%6.06.00.050.0%11.09.00.055.0%20.019.00.051.3%42.064.02.038.9%

Fundamentals of Enveric

About Enveric Biosciences Inc

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead program is EB-373, an active metabolite of psilocybin, which is in Phase 1 clinical trials for the treatment of anxiety disorders; EVM-301 for treating mental health; and EV104 CBD + Celecoxib conjugate for treating osteoarthritis. The company also developing cannabinoid-infused topical product for the treatment of radiodermatitis; and cannabinoid and COX-2 inhibitor conjugation that is in pre-clinical stage for the treatment of OA/acute pain. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Fundamental data was last updated by Penke on 2024-04-11 06:58:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Enveric Biosciences Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Enveric earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Enveric to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Enveric Biosciences Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-4.3%+4.3%
5Y-4.3%10Y-10.1%+5.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.2%+207.2%
TTM--216.8%+216.8%
YOY--282.3%+282.3%
5Y-4.3%-436.8%+432.5%
10Y-10.1%-597.3%+587.2%
1.1.2. Return on Assets

Shows how efficient Enveric is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Enveric to the Biotechnology industry mean.
  • -56.2% Return on Assets means that Enveric generated $-0.56 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Enveric Biosciences Inc:

  • The MRQ is -56.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -48.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-56.2%TTM-48.2%-8.0%
TTM-48.2%YOY-21.5%-26.7%
TTM-48.2%5Y-30.2%-18.0%
5Y-30.2%10Y-29.5%-0.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-56.2%-13.3%-42.9%
TTM-48.2%-12.8%-35.4%
YOY-21.5%-11.6%-9.9%
5Y-30.2%-13.8%-16.4%
10Y-29.5%-15.6%-13.9%
1.1.3. Return on Equity

Shows how efficient Enveric is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Enveric to the Biotechnology industry mean.
  • -91.0% Return on Equity means Enveric generated $-0.91 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Enveric Biosciences Inc:

  • The MRQ is -91.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -95.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-91.0%TTM-95.5%+4.4%
TTM-95.5%YOY-28.5%-66.9%
TTM-95.5%5Y-46.6%-48.8%
5Y-46.6%10Y-38.6%-8.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-91.0%-16.9%-74.1%
TTM-95.5%-16.1%-79.4%
YOY-28.5%-14.9%-13.6%
5Y-46.6%-19.3%-27.3%
10Y-38.6%-20.1%-18.5%

1.2. Operating Efficiency of Enveric Biosciences Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Enveric is operating .

  • Measures how much profit Enveric makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Enveric to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Enveric Biosciences Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-4.9%+4.9%
5Y-4.9%10Y-7.1%+2.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--298.0%+298.0%
TTM--238.5%+238.5%
YOY--288.4%+288.4%
5Y-4.9%-486.2%+481.3%
10Y-7.1%-628.4%+621.3%
1.2.2. Operating Ratio

Measures how efficient Enveric is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Enveric Biosciences Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y0.330-0.330
5Y0.33010Y0.577-0.247
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.235-3.235
TTM-3.310-3.310
YOY-3.838-3.838
5Y0.3305.679-5.349
10Y0.5777.823-7.246

1.3. Liquidity of Enveric Biosciences Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Enveric is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.29 means the company has $1.29 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Enveric Biosciences Inc:

  • The MRQ is 1.286. The company is just able to pay all its short-term debts.
  • The TTM is 1.957. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.286TTM1.957-0.671
TTM1.957YOY8.085-6.128
TTM1.9575Y4.452-2.495
5Y4.45210Y2.994+1.458
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2863.863-2.577
TTM1.9574.169-2.212
YOY8.0855.337+2.748
5Y4.4526.122-1.670
10Y2.9946.434-3.440
1.3.2. Quick Ratio

Measures if Enveric is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Enveric to the Biotechnology industry mean.
  • A Quick Ratio of 1.07 means the company can pay off $1.07 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Enveric Biosciences Inc:

  • The MRQ is 1.072. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.590. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.072TTM1.590-0.518
TTM1.590YOY7.676-6.086
TTM1.5905Y3.991-2.401
5Y3.99110Y2.661+1.330
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0723.504-2.432
TTM1.5903.991-2.401
YOY7.6765.371+2.305
5Y3.9916.088-2.097
10Y2.6616.395-3.734

1.4. Solvency of Enveric Biosciences Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Enveric assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Enveric to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.38 means that Enveric assets are financed with 38.3% credit (debt) and the remaining percentage (100% - 38.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Enveric Biosciences Inc:

  • The MRQ is 0.383. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.449. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.383TTM0.449-0.066
TTM0.449YOY0.222+0.227
TTM0.4495Y0.381+0.068
5Y0.38110Y0.589-0.207
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3830.339+0.044
TTM0.4490.337+0.112
YOY0.2220.271-0.049
5Y0.3810.368+0.013
10Y0.5890.388+0.201
1.4.2. Debt to Equity Ratio

Measures if Enveric is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Enveric to the Biotechnology industry mean.
  • A Debt to Equity ratio of 62.1% means that company has $0.62 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Enveric Biosciences Inc:

  • The MRQ is 0.621. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.944. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.621TTM0.944-0.323
TTM0.944YOY0.295+0.649
TTM0.9445Y0.790+0.154
5Y0.79010Y1.962-1.172
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6210.392+0.229
TTM0.9440.403+0.541
YOY0.2950.335-0.040
5Y0.7900.427+0.363
10Y1.9620.461+1.501

2. Market Valuation of Enveric Biosciences Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Enveric generates.

  • Above 15 is considered overpriced but always compare Enveric to the Biotechnology industry mean.
  • A PE ratio of -0.69 means the investor is paying $-0.69 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Enveric Biosciences Inc:

  • The EOD is -0.478. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.690. Based on the earnings, the company is expensive. -2
  • The TTM is -0.916. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.478MRQ-0.690+0.212
MRQ-0.690TTM-0.916+0.226
TTM-0.916YOY-0.955+0.039
TTM-0.9165Y-1.516+0.601
5Y-1.51610Y-56.894+55.377
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.478-2.300+1.822
MRQ-0.690-2.656+1.966
TTM-0.916-2.718+1.802
YOY-0.955-4.145+3.190
5Y-1.516-6.258+4.742
10Y-56.894-6.315-50.579
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Enveric Biosciences Inc:

  • The EOD is -0.937. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.354. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.226. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.937MRQ-1.354+0.417
MRQ-1.354TTM-1.226-0.128
TTM-1.226YOY-0.745-0.481
TTM-1.2265Y-3.053+1.827
5Y-3.05310Y17.663-20.716
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.937-2.974+2.037
MRQ-1.354-3.306+1.952
TTM-1.226-3.508+2.282
YOY-0.745-5.613+4.868
5Y-3.053-8.378+5.325
10Y17.663-8.873+26.536
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Enveric is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.51 means the investor is paying $2.51 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Enveric Biosciences Inc:

  • The EOD is 1.739. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.513. Based on the equity, the company is underpriced. +1
  • The TTM is 3.937. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD1.739MRQ2.513-0.773
MRQ2.513TTM3.937-1.424
TTM3.937YOY0.612+3.325
TTM3.9375Y2.163+1.773
5Y2.16310Y33.139-30.976
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.7391.914-0.175
MRQ2.5132.116+0.397
TTM3.9372.097+1.840
YOY0.6122.881-2.269
5Y2.1633.550-1.387
10Y33.1393.936+29.203
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Enveric Biosciences Inc.

3.1. Institutions holding Enveric Biosciences Inc

Institutions are holding 6.708% of the shares of Enveric Biosciences Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Armistice Capital, LLC5.05810.00482730002730000
2023-12-31AdvisorShares Investments, LLC2.62780.0432141833-5000-3.4052
2023-12-31BlackRock Inc0.54802957800
2023-12-31Vanguard Group Inc0.33720181981831.0158
2023-12-31Geode Capital Management, LLC0.24301311800
2023-12-31Tower Research Capital LLC0.23480.000212674305331.7327
2023-12-31Group One Trading, LP0.0051027300
2023-12-31Advisor Group Holdings, Inc.0.00280150-150-50
2023-12-31Bank of America Corp0.0019010000
2023-12-31Wells Fargo & Co0.0006033-1-2.9412
2023-12-31UBS Group AG0.0002010-301-96.7846
2023-12-31ORG Partners LLC0.0002010100
2023-12-31Morgan Stanley - Brokerage Accounts00100
2023-12-31Acadian Asset Management LLC000-4559-100
2023-09-30Royal Bank of Canada000-228-100
2023-12-31The Toronto-Dominion Bank000-108-100
2023-09-30Citadel Advisors Llc000-13933-100
2023-09-30Renaissance Technologies Corp000-17170-100
Total 9.05970.0482488978+234796+48.0%

3.2. Funds holding Enveric Biosciences Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-28AdvisorShares Psychedelics ETF3.27443.23382388335000026.4784
2023-09-30BlackRock Extended Mkt Composite0.2820.00032056800
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.249501819800
2024-03-31BlackRock Extended Equity Market K0.24610.00011795060.0334
2024-02-29Fidelity Extended Market Index0.156601142000
2024-03-31Extended Equity Market Fund M0.03040.00012214-4-0.1803
2024-02-29Fidelity Series Total Market Index0.0121088000
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.007050800
2024-02-29Fidelity Total Market Index0.0063046300
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.0056040810.2457
2023-12-31SSgA U.S. Extended Market Index Class I0.0045032600
2024-03-31State St US Extended Mkt Indx NL Cl C0.0045032600
2024-02-29Spartan Total Market Index Pool E0.0032023200
2023-12-31NT Ext Equity Mkt Idx Fd - L0.0031022300
2023-12-31Northern Trust Extended Eq Market Idx0.0031022300
2024-02-29Fidelity Nasdaq Composite Index0.001309600
2023-12-31SSgA U.S. Total Market Index Strategy0.0013094-2-2.0833
2024-02-29Spartan Extended Market Index Pool E0.000402700
2023-12-31NT Ext Eq Mkt Indx Fd DC Lending Tier 50.000201600
Total 4.29163.2343313005+50001+16.0%

3.3. Insider Transactions

Insiders are holding 7.06% of the shares of Enveric Biosciences Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-09-15Frank PasqualoneBUY10002.14

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Enveric Biosciences Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.183-0.404+320%-0.231+226%-0.048+126%0.013+1276%
Book Value Per Share--0.5170.771-33%2.955-82%2.010-74%1.589-67%
Current Ratio--1.2861.957-34%8.085-84%4.452-71%2.994-57%
Debt To Asset Ratio--0.3830.449-15%0.222+72%0.381+0%0.589-35%
Debt To Equity Ratio--0.6210.944-34%0.295+111%0.790-21%1.962-68%
Dividend Per Share----0%-0%6741.294-100%3464.420-100%
Eps---0.471-0.653+39%-0.562+19%-0.639+36%-0.441-6%
Free Cash Flow Per Share---0.240-0.483+101%-0.608+153%-0.321+34%-0.257+7%
Free Cash Flow To Equity Per Share---0.266-0.565+113%0.015-1825%-0.166-38%-0.070-74%
Gross Profit Margin--1.5381.134+36%1.000+54%128.471-99%66.423-98%
Intrinsic Value_10Y_max---12.995--------
Intrinsic Value_10Y_min---24.906--------
Intrinsic Value_1Y_max---1.069--------
Intrinsic Value_1Y_min---1.965--------
Intrinsic Value_3Y_max---3.389--------
Intrinsic Value_3Y_min---6.399--------
Intrinsic Value_5Y_max---5.924--------
Intrinsic Value_5Y_min---11.341--------
Market Cap6564600.000-44%9482200.00015890343.700-40%12480581.050-24%13460991.077-30%17832719.891-47%
Net Profit Margin----0%-0%-0.0430%-0.1010%
Operating Margin----0%-0%-0.0490%-0.0710%
Operating Ratio----0%-0%0.330-100%0.577-100%
Pb Ratio1.739-44%2.5133.937-36%0.612+311%2.163+16%33.139-92%
Pe Ratio-0.478+31%-0.690-0.916+33%-0.955+38%-1.516+120%-56.894+8146%
Price Per Share0.900-44%1.3002.179-40%1.711-24%1.764-26%2.403-46%
Price To Free Cash Flow Ratio-0.937+31%-1.354-1.226-9%-0.745-45%-3.053+126%17.663-108%
Price To Total Gains Ratio4.905-44%7.085-1.680+124%7.305-3%2.864+147%-196.243+2870%
Quick Ratio--1.0721.590-33%7.676-86%3.991-73%2.661-60%
Return On Assets---0.562-0.482-14%-0.215-62%-0.302-46%-0.295-47%
Return On Equity---0.910-0.955+5%-0.285-69%-0.466-49%-0.386-58%
Total Gains Per Share--0.183-0.404+320%-0.231+226%6741.246-100%3464.433-100%
Usd Book Value--3773976.0005624605.000-33%21550900.750-82%14709785.000-74%11615156.205-68%
Usd Book Value Change Per Share--0.183-0.404+320%-0.231+226%-0.048+126%0.013+1276%
Usd Book Value Per Share--0.5170.771-33%2.955-82%2.010-74%1.589-67%
Usd Dividend Per Share----0%-0%6741.294-100%3464.420-100%
Usd Eps---0.471-0.653+39%-0.562+19%-0.639+36%-0.441-6%
Usd Free Cash Flow---1751033.000-3524897.750+101%-4432722.000+153%-2338501.350+34%-1873757.513+7%
Usd Free Cash Flow Per Share---0.240-0.483+101%-0.608+153%-0.321+34%-0.257+7%
Usd Free Cash Flow To Equity Per Share---0.266-0.565+113%0.015-1825%-0.166-38%-0.070-74%
Usd Market Cap6564600.000-44%9482200.00015890343.700-40%12480581.050-24%13460991.077-30%17832719.891-47%
Usd Price Per Share0.900-44%1.3002.179-40%1.711-24%1.764-26%2.403-46%
Usd Profit---3435936.000-4309656.000+25%-4623761.750+35%-4823703.250+40%-3297185.718-4%
Usd Revenue----0%-0%678708.800-100%3848651.487-100%
Usd Total Gains Per Share--0.183-0.404+320%-0.231+226%6741.246-100%3464.433-100%
 EOD+2 -6MRQTTM+20 -10YOY+13 -175Y+12 -2210Y+12 -22

4.2. Fundamental Score

Let's check the fundamental score of Enveric Biosciences Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.478
Price to Book Ratio (EOD)Between0-11.739
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.072
Current Ratio (MRQ)Greater than11.286
Debt to Asset Ratio (MRQ)Less than10.383
Debt to Equity Ratio (MRQ)Less than10.621
Return on Equity (MRQ)Greater than0.15-0.910
Return on Assets (MRQ)Greater than0.05-0.562
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Enveric Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.723
Ma 20Greater thanMa 500.938
Ma 50Greater thanMa 1001.049
Ma 100Greater thanMa 2001.116
OpenGreater thanClose0.934
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets6,117
Total Liabilities2,344
Total Stockholder Equity3,774
 As reported
Total Liabilities 2,344
Total Stockholder Equity+ 3,774
Total Assets = 6,117

Assets

Total Assets6,117
Total Current Assets3,014
Long-term Assets3,104
Total Current Assets
Cash And Cash Equivalents 2,288
Net Receivables 225
Other Current Assets 501
Total Current Assets  (as reported)3,014
Total Current Assets  (calculated)3,014
+/-0
Long-term Assets
Property Plant Equipment 507
Long-term Assets Other 568
Long-term Assets  (as reported)3,104
Long-term Assets  (calculated)1,075
+/- 2,029

Liabilities & Shareholders' Equity

Total Current Liabilities2,344
Long-term Liabilities0
Total Stockholder Equity3,774
Total Current Liabilities
Accounts payable 1,219
Other Current Liabilities 1,125
Total Current Liabilities  (as reported)2,344
Total Current Liabilities  (calculated)2,344
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock27
Retained Earnings -96,500
Accumulated Other Comprehensive Income -570
Other Stockholders Equity 100,816
Total Stockholder Equity (as reported)3,774
Total Stockholder Equity (calculated)3,774
+/-0
Other
Capital Stock27
Cash and Short Term Investments 2,288
Common Stock Shares Outstanding 2,349
Liabilities and Stockholders Equity 6,117
Net Debt -2,288
Net Invested Capital 1,956
Net Working Capital 1,238
Property Plant and Equipment Gross 865



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-311999-03-311998-12-311998-09-301998-06-301998-03-311997-12-311997-09-301997-06-301997-03-311996-12-311996-09-301996-06-301996-03-311995-12-311995-09-301995-06-301995-03-311994-09-301994-06-301994-03-311993-12-311993-09-30
> Total Assets 
0
0
0
2,700
0
0
0
0
4,400
3,700
6,300
5,200
4,141
4,900
3,700
3,200
0
3,165
3,600
2,800
0
893
2,540
2,432
2,542
2,457
2,349
1,976
1,742
1,753
1,740
1,805
1,794
1,746
1,610
1,414
1,326
1,205
1,065
992
1,425
1,464
1,264
1,150
1,068
897
611
596
533
464
942
1,103
1,652
1,605
1,535
98
90
70
36
14
46
2
10
3
4
1
6
8
24
22
10
6
6
6
5
7
5
4
27
12
9
5
4
10,437
21,207
12,631
15,143
38,122
39,508
49,680
47,293
47,137
52,197
52,197
45,542
45,899
29,637
30,507
29,478
26,656
25,005
27,136
27,506
27,994
4,097
4,097
23,695
69,758
26,719
32,179
28,572
30,855
19,553
15,852
9,800
6,619
6,117
6,1176,6199,80015,85219,55330,85528,57232,17926,71969,75823,6954,0974,09727,99427,50627,13625,00526,65629,47830,50729,63745,89945,54252,19752,19747,13747,29349,68039,50838,12215,14312,63121,20710,43745912274575666102224861431024614367090981,5351,6051,6521,1039424645335966118971,0681,1501,2641,4641,4259921,0651,2051,3261,4141,6101,7461,7941,8051,7401,7531,7421,9762,3492,4572,5422,4322,54089302,8003,6003,16503,2003,7004,9004,1415,2006,3003,7004,40000002,700000
   > Total Current Assets 
0
0
0
2,400
0
0
0
0
3,900
3,000
5,300
4,200
2,966
3,600
2,400
1,900
0
1,923
2,300
1,400
0
472
2,188
2,074
2,168
2,001
1,910
1,564
1,315
1,445
1,391
1,475
1,462
1,441
1,331
1,162
1,090
971
838
772
1,223
1,268
1,081
976
904
740
464
443
389
329
813
975
1,652
1,605
1,535
98
90
70
36
14
46
2
10
3
4
1
6
8
24
22
10
6
6
6
5
7
5
4
27
12
9
5
4
9,328
14,481
5,753
8,218
11,268
10,065
12,352
10,752
11,415
14,645
14,645
9,603
10,594
10,061
11,459
10,966
8,688
7,599
10,244
10,269
11,305
2,279
2,279
21,509
22,282
17,737
22,665
19,369
22,267
18,432
14,839
8,900
5,827
3,014
3,0145,8278,90014,83918,43222,26719,36922,66517,73722,28221,5092,2792,27911,30510,26910,2447,5998,68810,96611,45910,06110,5949,60314,64514,64511,41510,75212,35210,06511,2688,2185,75314,4819,32845912274575666102224861431024614367090981,5351,6051,6529758133293894434647409049761,0811,2681,2237728389711,0901,1621,3311,4411,4621,4751,3911,4451,3151,5641,9102,0012,1682,0742,18847201,4002,3001,92301,9002,4003,6002,9664,2005,3003,0003,90000002,400000
       Cash And Cash Equivalents 
0
0
0
1,800
0
0
0
0
3,100
2,100
2,800
2,900
1,587
2,400
1,400
800
0
577
600
300
0
264
1,713
1,505
1,519
1,468
1,433
945
771
869
878
967
917
859
894
788
657
590
647
371
920
871
874
729
674
551
352
297
273
229
726
813
614
582
1,527
96
87
67
36
13
46
2
10
3
4
1
2
4
20
18
6
2
2
1
1
2
1
0
22
8
9
5
4
4,378
5,067
505
3,604
2,914
1,380
1,813
1,041
844
4,882
4,882
915
2,064
1,371
1,723
1,601
500
431
1,267
2,088
2,840
1,578
1,578
20,618
21,448
17,356
21,695
18,009
21,201
17,724
12,562
7,081
4,267
2,288
2,2884,2677,08112,56217,72421,20118,00921,69517,35621,44820,6181,5781,5782,8402,0881,2674315001,6011,7231,3712,0649154,8824,8828441,0411,8131,3802,9143,6045055,0674,378459822012112261820421431024613366787961,5275826148137262292732973525516747298748719203716475906577888948599179678788697719451,4331,4681,5191,5051,713264030060057708001,4002,4001,5872,9002,8002,1003,10000001,800000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,000
1,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
83
83
83
83
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000008383838300000000000000000000000000000000001,0001,0000000000000000000000000000000000000000000000000000000
       Net Receivables 
0
0
0
300
0
0
0
0
400
500
600
700
821
800
700
800
0
912
1,200
600
0
135
448
496
580
507
449
530
489
443
457
457
484
499
346
246
327
345
183
345
208
326
171
180
187
155
95
84
70
75
46
35
0
75
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,684
8,956
4,929
4,134
7,725
8,060
9,590
8,720
9,167
8,838
8,838
7,937
7,829
7,871
8,900
8,545
7,609
6,384
8,102
7,295
7,563
0
0
0
0
0
0
0
0
0
0
0
0
225
2250000000000007,5637,2958,1026,3847,6098,5458,9007,8717,8297,9378,8388,8389,1678,7209,5908,0607,7254,1344,9298,9564,6840000000000000000000000000000075035467570849515518718017132620834518334532724634649948445745744348953044950758049644813506001,20091208007008008217006005004000000300000
       Other Current Assets 
0
0
0
0
0
0
0
0
100
100
1,600
300
261
200
200
200
0
147
400
400
0
66
14
60
57
26
0
0
55
153
56
50
62
83
92
127
106
35
8
56
95
71
36
67
42
34
16
62
47
25
41
72
38
23
8
3
3
3
0
1
0
0
0
0
0
0
4
4
4
4
4
4
4
4
4
4
4
4
4
4
0
0
0
267
458
319
481
630
542
867
908
1,321
0
924
752
701
819
836
820
579
784
875
887
901
0
701
891
833
381
971
1,360
1,066
708
2,277
1,819
1,560
501
5011,5601,8192,2777081,0661,360971381833891701090188787578457982083681970175292401,32190886754263048131945826700044444444444444000000103338233872412547621634426736719556835106127928362505615355002657601466040040014702002002002613001,60010010000000000
   > Long-term Assets 
0
0
0
300
0
0
0
0
500
700
1,000
1,000
1,175
1,300
1,300
1,300
0
1,242
1,300
1,400
0
421
351
358
374
456
439
411
427
308
349
330
331
305
280
252
235
235
227
220
202
196
183
173
164
157
147
153
143
135
129
127
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,109
6,726
6,878
6,925
26,854
29,443
37,328
36,541
35,722
37,552
37,552
35,938
35,306
19,576
19,048
18,512
17,968
17,406
16,892
17,237
16,689
1,818
1,818
2,186
47,476
8,982
9,514
9,203
8,589
1,121
1,013
900
792
3,104
3,1047929001,0131,1218,5899,2039,5148,98247,4762,1861,8181,81816,68917,23716,89217,40617,96818,51219,04819,57635,30635,93837,55237,55235,72236,54137,32829,44326,8546,9256,8786,7261,109000000000000000500000000000000012712913514315314715716417318319620222022723523525228030533133034930842741143945637435835142101,4001,3001,24201,3001,3001,3001,1751,0001,0007005000000300000
       Property Plant Equipment 
0
0
0
200
0
0
0
0
300
300
600
600
623
700
700
600
0
587
500
500
0
184
117
113
124
108
93
90
75
51
40
97
92
71
60
52
46
42
38
38
34
30
29
26
22
18
14
10
6
3
3
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30
77
135
129
115
100
114
108
93
95
95
73
60
59
58
60
65
83
116
1,012
966
0
0
0
141
471
928
904
802
741
676
605
539
507
5075396056767418029049284711410009661,0121168365605859607395959310811410011512913577300000000000000000000000000000000333610141822262930343838424652607192974051759093108124113117184050050058706007007006236006003003000000200000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,471
3,671
3,820
17,379
17,089
21,880
21,887
21,887
21,898
21,898
21,898
21,898
13,730
13,730
13,730
13,730
13,730
13,730
13,730
13,730
0
0
0
9,062
1,588
1,611
1,562
1,468
0
0
0
0
0
000001,4681,5621,6111,5889,06200013,73013,73013,73013,73013,73013,73013,73013,73021,89821,89821,89821,89821,88721,88721,88017,08917,3793,8203,6713,471000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
200
300
400
400
0
500
500
600
0
700
800
800
0
0
203
212
0
303
304
305
300
256
309
233
237
226
213
201
190
192
189
182
168
167
154
147
141
139
133
142
137
131
126
124
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,072
3,158
3,073
2,976
9,360
8,765
11,846
11,058
10,253
9,470
9,470
7,879
7,249
5,778
5,230
4,681
4,133
3,584
3,036
2,487
1,951
1,818
1,818
2,186
38,274
6,924
6,975
6,736
6,319
380
337
295
253
0
02532953373806,3196,7366,9756,92438,2742,1861,8181,8181,9512,4873,0363,5844,1334,6815,2305,7787,2497,8799,4709,47010,25311,05811,8468,7659,3602,9763,0733,1581,07200000000000000000000000000000001241261311371421331391411471541671681821891921902012132262372333092563003053043030212203008008007000600500500040040030020000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
917
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000091700000000000000000000000000000000000-50000000000000000000000000000000000000000000000000000000000000000000
> Total Liabilities 
0
0
0
2,400
0
0
0
0
700
600
700
600
873
700
600
800
0
1,640
1,400
1,700
0
2,447
1,177
958
922
806
693
416
358
342
307
369
347
317
256
272
290
250
233
283
797
666
456
284
166
180
67
115
113
87
332
229
46
48
42
7
7
21
9
1
38
12
35
33
40
51
67
72
8
18
10
10
15
26
30
35
38
25
5
2
2
9
10
9,318
20,248
13,431
12,731
33,370
27,844
34,910
33,673
34,918
32,748
32,748
27,238
15,806
18,878
19,345
18,617
13,409
14,384
16,913
14,627
14,818
681
681
4,876
14,391
4,413
7,737
5,969
7,254
3,996
4,438
4,926
4,184
2,344
2,3444,1844,9264,4383,9967,2545,9697,7374,41314,3914,87668168114,81814,62716,91314,38413,40918,61719,34518,87815,80627,23832,74832,74834,91833,67334,91027,84433,37012,73113,43120,2489,3181092252538353026151010188726751403335123819217742484622933287113115671801662844566667972832332502902722563173473693073423584166938069229581,1772,44701,7001,4001,640080060070087360070060070000002,400000
   > Total Current Liabilities 
0
0
0
2,400
0
0
0
0
700
600
700
700
873
700
700
700
0
1,607
1,400
1,700
0
2,447
1,177
958
922
806
693
416
358
342
307
369
347
316
255
271
221
178
174
238
765
665
455
283
165
180
67
115
113
87
332
229
46
48
42
7
7
21
9
1
38
12
35
33
40
51
67
72
8
18
10
10
15
26
30
35
38
25
5
2
2
9
10
4,318
14,848
7,931
7,231
13,615
12,709
17,268
15,593
31,492
30,368
30,368
25,061
12,865
14,689
14,705
14,366
13,409
14,384
16,913
12,769
13,993
681
681
1,168
2,163
2,084
2,094
2,325
2,598
3,996
4,438
4,926
4,184
2,344
2,3444,1844,9264,4383,9962,5982,3252,0942,0842,1631,16868168113,99312,76916,91314,38413,40914,36614,70514,68912,86525,06130,36830,36831,49215,59317,26812,70913,6157,2317,93114,8484,3181092252538353026151010188726751403335123819217742484622933287113115671801652834556657652381741782212712553163473693073423584166938069229581,1772,44701,7001,4001,607070070070087370070060070000002,400000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
136
100
100
100
0
464
100
300
0
872
352
352
352
34
338
113
113
113
113
113
113
113
113
167
44
38
38
38
74
66
40
67
36
10
0
34
24
10
0
34
24
10
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8
20
25
29
2
2
0
0
0
0
0
250
1,477
1,407
4,137
3,494
4,356
4,511
4,172
0
4,803
2,749
3,607
5,207
5,187
5,015
4,433
4,881
8,053
5,441
6,857
0
0
149
0
107
111
111
89
64
37
10
0
0
00103764891111111070149006,8575,4418,0534,8814,4335,0155,1875,2073,6072,7494,80304,1724,5114,3563,4944,1371,4071,47725000000222925208000000000000000000010243401024340103667406674383838441671131131131131131131131133383435235235287203001004640100100100136000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,881
8,053
5,232
6,648
0
0
149
0
0
0
0
0
0
0
0
0
0
0000000000149006,6485,2328,0534,8810000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
200
0
0
0
0
200
300
400
400
404
300
300
400
0
651
300
400
0
336
136
34
28
52
40
19
18
15
13
67
62
39
32
0
41
21
40
11
17
72
79
24
26
14
9
25
18
32
0
45
0
1
32
1
1
5
7
0
37
12
3
1
0
3
0
8
8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,427
3,561
2,587
3,220
4,907
5,131
4,469
3,945
4,126
0
7,908
4,870
4,216
4,378
5,079
4,946
4,713
4,696
5,254
4,867
4,580
681
681
1,019
2,163
683
1,218
754
710
463
1,793
1,234
1,098
1,219
1,2191,0981,2341,7934637107541,2186832,1631,0196816814,5804,8675,2544,6964,7134,9465,0794,3784,2164,8707,90804,1263,9454,4695,1314,9073,2202,5873,5613,42700000000000000880301312370751132104503218259142624797217114021410323962671315181940522834136336040030065104003003004044004003002000000200000
       Other Current Liabilities 
0
0
0
2,200
0
0
0
0
500
300
300
300
333
300
300
200
0
491
1,000
1,000
0
784
690
572
542
721
190
181
170
173
88
75
72
164
110
104
136
119
97
189
126
136
101
113
103
155
58
56
70
45
19
150
22
37
11
6
6
16
2
1
1
0
33
33
40
48
67
65
0
18
10
10
15
18
10
10
10
23
3
2
2
9
10
891
1,817
3,867
2,604
4,571
-3,484,876
8,443
7,136
23,194
0
-6,071,094
17,442
5,042
-9,393,896
4,439
4,404
4,263
-8,874,194
3,605
2,460
2,556
0
681
1,019
2,163
1,293
764
1,459
1,799
3,469
2,608
2,182
3,085
1,125
1,1253,0852,1822,6083,4691,7991,4597641,2932,1631,01968102,5562,4603,605-8,874,1944,2634,4044,439-9,393,8965,04217,442-6,071,094023,1947,1368,443-3,484,8764,5712,6043,8671,81789110922323101010181510101806567484033330112166611372215019457056581551031131011361261899711913610411016472758817317018119072154257269078401,0001,000491020030030033330030030050000002,200000
   > Long-term Liabilities 
0
0
0
200
0
0
0
0
200
300
400
400
540
400
400
500
0
33
400
700
0
1,208
487
386
380
86
378
131
130
127
125
180
175
1
1
1
69
72
59
45
32
1
1
1
1
25
9
59
43
42
313
79
24
11
32
1
1
5
7
0
37
12
3
1
0
3
0
8
8
0
0
0
0
8
20
25
29
2
2
0
0
0
0
5,000
5,400
5,500
5,500
19,755
15,135
17,642
18,080
3,425
2,381
2,381
2,177
2,942
4,189
4,640
4,251
9,146
9,577
13,308
1,858
825
0
6,168
3,708
12,228
2,330
5,644
3,644
4,655
527
10,406
0
0
0
00010,4065274,6553,6445,6442,33012,2283,7086,16808251,85813,3089,5779,1464,2514,6404,1892,9422,1772,3812,3813,42518,08017,64215,13519,7555,5005,5005,4005,0000000222925208000088030131237075113211247931342435992511113245597269111175180125127130131378863803864871,20807004003305004004005404004003002000000200000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,168
3,708
12,228
2,261
5,604
3,634
4,655
0
0
0
0
0
000004,6553,6345,6042,26112,2283,7086,168000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
300
0
0
0
0
3,700
3,100
5,600
4,600
3,268
4,200
3,100
2,400
0
1,525
2,200
1,100
0
-1,553
1,362
1,474
1,620
1,651
1,656
1,560
1,384
1,412
1,433
1,436
1,447
1,429
1,354
1,142
1,035
955
832
708
628
798
808
865
902
717
544
481
420
377
610
873
1,606
1,557
1,493
91
83
48
27
13
9
-10
-26
-30
-36
-50
-61
-64
17
5
1
-4
-8
-20
-25
-29
-33
-20
22
10
7
-4
-6
1,118
959
-800
2,412
4,753
11,660
14,774
13,608
12,201
0
19,445
18,303
30,093
10,759
11,162
10,861
13,247
10,622
10,223
12,880
13,176
3,416
3,416
18,819
55,367
22,306
24,442
21,965
22,840
14,672
10,406
4,875
2,436
3,774
3,7742,4364,87510,40614,67222,84021,96524,44222,30655,36718,8193,4163,41613,17612,88010,22310,62213,24710,86111,16210,75930,09318,30319,445012,20113,60814,77411,6604,7532,412-8009591,118-6-471022-20-33-29-25-20-8-41517-64-61-50-36-30-26-10913274883911,4931,5571,6068736103774204815447179028658087986287088329551,0351,1421,3541,4291,4471,4361,4331,4121,3841,5601,6561,6511,6201,4741,362-1,55301,1002,2001,52502,4003,1004,2003,2684,6005,6003,1003,7000000300000
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
191
0
0
0
0
214
0
0
0
258
467
467
468
471
471
474
474
474
474
474
474
474
474
474
474
470
470
470
470
470
470
470
470
470
470
470
470
470
470
650
650
650
650
650
650
650
650
65
65
650
65
65
65
65
65
65
121
121
121
121
121
121
121
121
121
121
154
121
121
154
154
116
116
119
135
139
139
146
147
159
0
182
190
229
423
503
524
628
25
32
52
57
101
101
214
314
326
526
11
21
21
21
21
22
27
2722212121211152632631421410110157523225628524503423229190182015914714613913913511911611615415412112115412112112112112112112112112112165656565656565065656506506506506506506506504704704704704704704704704704704704704704704744744744744744744744744744744714714684674672580002140000191000000000000
   Retained Earnings Total Equity000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-534
0
0
-534
-565
0
0
-565
-603
0
0
-615
-619
0
0
-624
-634
0
0
0
0
0
0
0
-1,365
0
0
0
0
0
0
0
-65
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
90
0
0
-288
-7
1
-4
-19
0
37
34
36
87
106
88
70
60
25
40
52
-181
-181
-179
-185
-31
58
-223
-640
-537
-535
-546
-536
-570
-570-536-546-535-537-640-22358-31-185-179-181-181524025607088106873634370-19-41-7-2880090000000000000000000-650000000-1,3650000000-634-62400-619-61500-603-56500-565-53400-534000000000000000000000000000000000
   Capital Surplus 000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
5,900
0
0
0
0
13,800
13,900
18,200
18,300
38,528
40,700
40,700
40,700
0
41,482
44,400
44,400
0
44,151
46,332
46,332
46,373
46,405
46,405
46,403
46,403
46,403
46,403
46,403
46,403
46,403
46,403
46,403
46,403
46,429
46,429
46,429
46,429
46,429
46,429
46,429
46,429
46,430
46,430
46,430
46,430
46,442
46,442
46,375
46,635
46,635
46,635
46,635
46,635
46,635
45,270
45,855
45,855
46,635
47,220
47,220
47,220
47,220
47,220
47,220
47,248
47,251
47,251
47,251
47,251
47,251
47,251
47,251
47,251
47,251
47,268
47,301
47,301
47,268
47,268
53
53
1,294
5,700
10,043
15,359
19,850
22,290
25,488
0
34,220
36,566
44,432
44,723
46,993
48,052
50,418
51,040
52,562
56,870
58,219
-181
15,223
34,702
73,869
82,747
89,118
90,228
93,990
94,396
94,805
95,641
96,013
100,816
100,81696,01395,64194,80594,39693,99090,22889,11882,74773,86934,70215,223-18158,21956,87052,56251,04050,41848,05246,99344,72344,43236,56634,220025,48822,29019,85015,35910,0435,7001,294535347,26847,26847,30147,30147,26847,25147,25147,25147,25147,25147,25147,25147,25147,25147,24847,22047,22047,22047,22047,22047,22046,63545,85545,85545,27046,63546,63546,63546,63546,63546,63546,37546,44246,44246,43046,43046,43046,43046,42946,42946,42946,42946,42946,42946,42946,42946,40346,40346,40346,40346,40346,40346,40346,40346,40346,40346,40546,40546,37346,33246,33244,151044,40044,40041,482040,70040,70040,70038,52818,30018,20013,90013,80000005,900000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-408
Gross Profit-408-408
 
Operating Income (+$)
Gross Profit-408
Operating Expense-16,040
Operating Income-16,448-16,448
 
Operating Expense (+$)
Research Development7,252
Selling General Administrative8,852
Selling And Marketing Expenses64
Operating Expense16,04016,169
 
Net Interest Income (+$)
Interest Income4
Interest Expense-4
Other Finance Cost-3
Net Interest Income3
 
Pretax Income (+$)
Operating Income-16,448
Net Interest Income3
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-17,263-15,634
EBIT - interestExpense = -16,452
-17,282
-17,307
Interest Expense4
Earnings Before Interest and Taxes (EBIT)-16,448-17,259
Earnings Before Interest and Taxes (EBITDA)-16,040
 
After tax Income (+$)
Income Before Tax-17,263
Tax Provision--1,479
Net Income From Continuing Ops-22,534-15,783
Net Income-17,311
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses16,448
Total Other Income/Expenses Net-814-3
 

Technical Analysis of Enveric
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Enveric. The general trend of Enveric is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Enveric's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Enveric Biosciences Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.01 < 1.03 < 1.19.

The bearish price targets are: 0.83 > 0.649.

Tweet this
Enveric Biosciences Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Enveric Biosciences Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Enveric Biosciences Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Enveric Biosciences Inc. The current macd is -0.04732798.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Enveric price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Enveric. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Enveric price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Enveric Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) ChartEnveric Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Enveric Biosciences Inc. The current adx is 40.58.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Enveric shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Enveric Biosciences Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Enveric Biosciences Inc. The current sar is 0.833.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Enveric Biosciences Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Enveric Biosciences Inc. The current rsi is 44.72. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Enveric Biosciences Inc Daily Relative Strength Index (RSI) ChartEnveric Biosciences Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Enveric Biosciences Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Enveric price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Enveric Biosciences Inc Daily Stochastic Oscillator ChartEnveric Biosciences Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Enveric Biosciences Inc. The current cci is -55.15750931.

Enveric Biosciences Inc Daily Commodity Channel Index (CCI) ChartEnveric Biosciences Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Enveric Biosciences Inc. The current cmo is -10.58766688.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Enveric Biosciences Inc Daily Chande Momentum Oscillator (CMO) ChartEnveric Biosciences Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Enveric Biosciences Inc. The current willr is -74.62686567.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Enveric is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Enveric Biosciences Inc Daily Williams %R ChartEnveric Biosciences Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Enveric Biosciences Inc.

Enveric Biosciences Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Enveric Biosciences Inc. The current atr is 0.11226873.

Enveric Biosciences Inc Daily Average True Range (ATR) ChartEnveric Biosciences Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Enveric Biosciences Inc. The current obv is 439,030,519.

Enveric Biosciences Inc Daily On-Balance Volume (OBV) ChartEnveric Biosciences Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Enveric Biosciences Inc. The current mfi is 49.55.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Enveric Biosciences Inc Daily Money Flow Index (MFI) ChartEnveric Biosciences Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Enveric Biosciences Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-01RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-21MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-03CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-25STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Enveric Biosciences Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Enveric Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.723
Ma 20Greater thanMa 500.938
Ma 50Greater thanMa 1001.049
Ma 100Greater thanMa 2001.116
OpenGreater thanClose0.934
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Enveric with someone you think should read this too:
  • Are you bullish or bearish on Enveric? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Enveric? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Enveric Biosciences Inc

I send you an email if I find something interesting about Enveric Biosciences Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Enveric Biosciences Inc.

Receive notifications about Enveric Biosciences Inc in your mailbox!